Functional_JJ Characterization_NN of_IN Brucella_NP melitensis_NP NorMI_NP ,_, an_DT Efflux_NP Pump_NP Belonging_NP to_TO the_DT Multidrug_NP and_CC Toxic_NP Compound_NN Extrusion_NP Family_NP Two_NP putative_JJ proteins_NNS (_( NorMI_NP and_CC NorMII_NP )_) similar_JJ to_TO the_DT multidrug_NN efflux_NN protein_NN NorM_NN of_IN Vibrio_NP parahaemolyticus_NNS are_VBP encoded_VBN by_IN the_DT Brucella_NP melitensis_NN 16_CD M_NN genome_NN ._SENT We_PP show_VBP that_IN a_DT drug-hypersusceptible_JJ Escherichia_NP coli_NNS strain_VBP overexpressing_VBG NorMI_NP displays_NNS increased_VBD resistance_NN to_TO norfloxacin_NN ,_, ciprofloxacin_NP ,_, gentamicin_NN ,_, tetraphenylphosphonium_NN ion_NN ,_, acriflavine_NN ,_, and_CC berberine_NN ._SENT This_DT elevated_JJ resistance_NN was_VBD proven_VBN to_TO be_VB mediated_VBN by_IN an_DT energy-dependent_JJ efflux_NN mechanism_NN ._SENT NorMI_NP belongs_VBZ to_TO the_DT multidrug_NN and_CC toxic_JJ compound_JJ extrusion_NN family_NN and_CC is_VBZ the_DT first_JJ multidrug_NN efflux_NN protein_NN identified_VBN in_IN Brucella_NP spp._NP Although_IN brucellosis_NN is_VBZ primarily_RB a_DT disease_NN of_IN domestic_JJ animals_NNS ,_, it_PP is_VBZ still_RB a_DT common_JJ human_JJ disease_NN in_IN many_JJ developing_VBG countries_NNS ._SENT The_DT pathogens_NNS responsible_JJ for_IN brucellosis_NN ,_, Brucella_NP spp._NP ,_, are_VBP facultative_JJ intracellular_JJ bacteria_NNS ._SENT Therefore_RB ,_, to_TO be_VB effective_JJ ,_, the_DT treatment_NN of_IN acute_JJ brucellosis_NN requires_VBZ drugs_NNS that_WDT penetrate_VBP macrophages_NNS ._SENT With_IN conventional_JJ drugs_NNS such_JJ as_IN tetracycline_NN ,_, aminoglycosides_NNS ,_, or_CC sulfonamides_NNS ,_, high_JJ relapse_NN rates_NNS have_VBP been_VBN reported_VBN ._SENT More_RBR recently_RB ,_, increasing_VBG resistance_NN of_IN Brucella_NP spp._NP to_TO co-trimoxazole_NN was_VBD reported_VBN ._SENT This_DT has_VBZ led_VBN to_TO the_DT search_NN for_IN new_JJ drugs_NNS which_WDT penetrate_VBP eukaryotic_JJ cells_NNS more_RBR efficiently_RB ._SENT The_DT broad-spectrum_NN in_IN vitro_NN activity_NN of_IN fluoroquinolones_NNS such_JJ as_IN ciprofloxacin_NN ,_, as_RB well_RB as_IN their_PP$ oral_JJ bioavailability_NN and_CC their_PP$ excellent_JJ intracellular_JJ penetration_NN ,_, initially_RB made_VBD them_PP very_RB promising_JJ for_IN treating_VBG brucellosis_NN ._SENT However_RB ,_, a_DT lack_NN of_IN effective_JJ bactericidal_JJ activity_NN of_IN fluoroquinolones_NNS against_IN Brucella_NP spp._NP ,_, an_DT appreciable_JJ rate_NN of_IN relapse_NN of_IN patients_NNS treated_VBN with_IN ciprofloxacin_NN ,_, and_CC development_NN of_IN ciprofloxacin_NN resistance_NN associated_VBN with_IN cross-resistance_NN to_TO other_JJ fluoroquinolones_NNS in_IN Brucella_NP melitensis_NN during_IN ciprofloxacin_NN therapy_NN have_VBP been_VBN also_RB reported_VBN ._SENT Nothing_NN is_VBZ known_VBN about_IN the_DT mechanism_NN of_IN fluoroquinolone_JJ resistance_NN development_NN in_IN B._NP melitensis_NN ._SENT In_IN other_JJ bacteria_NNS ,_, resistance_NN to_TO fluoroquinolones_NNS usually_RB results_VBZ from_IN multiple_JJ mutations_NNS in_IN genes_NNS encoding_VBG their_PP$ intracellular_JJ targets_NNS ,_, gyrase_NN and_CC topoisomerase_NN IV_NP ._SENT In_IN addition_NN to_TO this_DT mechanism_NN ,_, which_WDT is_VBZ antibiotic_JJ specific_NN ,_, a_DT more_RBR general_JJ mechanism_NN involves_VBZ multidrug_NN efflux_NN pumps_NNS which_WDT exclude_VBP toxic_JJ compounds_NNS ,_, including_VBG antibiotics_NNS ,_, from_IN the_DT cells_NNS ._SENT Some_DT of_IN these_DT pumps_NNS exhibit_VBP low_JJ specificity_NN and_CC confer_VB resistance_NN to_TO several_JJ unrelated_JJ antibiotics_NNS when_WRB they_PP are_VBP overexpressed_JJ ._SENT These_DT bacterial_JJ pumps_NNS are_VBP classified_VBN in_IN five_CD large_JJ ,_, ubiquitous_JJ superfamilies_NNS ._SENT One_CD of_IN these_DT ,_, the_DT multidrug_NN and_CC toxic_JJ compound_JJ extrusion_NN (_( MATE_JJ )_) family_NN ,_, was_VBD recently_RB identified_VBN ._SENT It_PP includes_VBZ several_JJ bacterial_JJ members_NNS but_CC also_RB eukaryotic_JJ proteins_NNS from_IN fungi_NNS and_CC plants_NNS ._SENT Among_IN these_DT ,_, only_RB a_DT few_JJ have_VBP been_VBN functionally_RB characterized_VBN ._SENT Four_CD bacterial_JJ members_NNS ,_, NorM_NP and_CC VmrA_NP of_IN Vibrio_NP parahaemolyticus_NP ,_, YdhE_NP of_IN Escherichia_NP coli_NNS ,_, and_CC BexA_NP of_IN Bacteroides_NP thetaiotaomicron_NP ,_, have_VBP been_VBN reported_VBN to_TO mediate_VB multidrug_NN resistance_NN (_( ,_, -_: )_) ._SENT NorM_NN and_CC VmrA_NP were_VBD also_RB reported_VBN to_TO function_VB by_IN a_DT drug:Na+_JJ antiport_NN mechanism_NN ._SENT Among_IN the_DT eukaryotic_JJ members_NNS ,_, the_DT only_JJ two_CD functionally_RB characterized_VBN proteins_NNS are_VBP yeast_NN Erc1_NN ,_, which_WDT confers_VBZ resistance_NN to_TO the_DT methionine_NN analog_NN ethionine_NN ,_, and_CC Arabidopsis_NP Alf5_NP ,_, conferring_VBG resistance_NN to_TO toxins_NNS ._SENT Proteins_NNS of_IN the_DT MATE_JJ family_NN have_VBP a_DT common_JJ predicted_VBN topology_NN with_IN 12_CD transmembrane_NN helices_NNS ._SENT A_DT B._NP melitensis_NN homolog_NN of_IN NorM_NP was_VBD recently_RB identified_VBN as_IN a_DT potential_JJ virulence_NN factor_NN ,_, as_IN strains_NNS with_IN mutations_NNS in_IN its_PP$ gene_NN could_MD not_RB be_VB recovered_VBN from_IN animals_NNS infected_VBN with_IN pools_NNS of_IN signature_NN tag_NN mutants_NNS (_( M._NP S._NP Zygmunt_NP ,_, S._NP D._NP Hagius_NP ,_, W._NP T._NP Fulton_NP ,_, J._NP V._NP Walker_NP ,_, N._NP J._NP Booth_NP ,_, and_CC P._NP H._NP Elzer_NP ,_, Brucellosis_NP 2000_CD ,_, 53rd_NP Brucellosis_NP Research_NP Conference_NP ,_, abstr_NP ._SENT 56_CD ,_, 2000_CD )_) ._SENT In_IN the_DT present_JJ work_NN ,_, we_PP functionally_RB characterized_VBD this_DT transporter_NN and_CC confirmed_VBD that_IN it_PP belongs_VBZ to_TO the_DT MATE_JJ family_NN ._SENT By_IN searching_VBG for_IN homology_NN with_IN the_DT NorM_NP multidrug_NN efflux_NN protein_NN of_IN V._NP parahaemolyticus_NP (_( BlastP_NP )_) in_IN the_DT B._NP melitensis_NN 16_CD M_NP genomic_JJ database_NN (_( accession_NN numbers_NNS and_CC )_) ,_, we_PP found_VBD that_IN two_CD putative_JJ multidrug_NN efflux_NN pumps_NNS belonging_VBG to_TO the_DT MATE_JJ family_NN are_VBP encoded_VBN by_IN this_DT genome_NN ._SENT The_DT first_JJ one_CD ,_, which_WDT we_PP named_VBD NorMI_NP ,_, is_VBZ encoded_VBN by_IN gene_NN BMEI1585_NP and_CC corresponds_VBZ to_TO the_DT above-mentioned_JJ protein_NN that_WDT was_VBD recently_RB identified_VBN as_IN a_DT potential_JJ virulence_NN factor_NN ._SENT The_DT second_NN ,_, which_WDT we_PP named_VBD NorMII_NP ,_, is_VBZ encoded_VBN by_IN gene_NN BMEI1612_NP ._SENT NorMI_NP and_CC NorMII_NP share_NN 27.7_CD and_CC 19.9_CD %_NN identical_JJ amino_NN acids_NNS (_( in_IN an_DT overlap_VBP of_IN 448_CD amino_NN acids_NNS )_) ,_, respectively_RB ,_, with_IN the_DT NorM_NP protein_NN of_IN V._NP parahaemolyticus_NN ._SENT As_IN NorMI_NP is_VBZ more_RBR similar_JJ to_TO NorM_NP than_IN NorMII_NP ,_, and_CC consequently_RB is_VBZ more_RBR likely_JJ to_TO have_VB a_DT similar_JJ function_NN ,_, we_PP focused_VBD this_DT work_NN on_IN NorMI_NP ._SENT To_TO confirm_VB that_IN NorMI_NP belongs_VBZ to_TO the_DT MATE_JJ family_NN ,_, we_PP searched_VBD (_( with_IN BlastP_NP )_) the_DT EMBL_NP redundant_JJ protein_NN database_NN to_TO determine_VB whether_IN NorMI_NP is_VBZ also_RB homologous_JJ to_TO other_JJ proteins_NNS of_IN this_DT family_NN ._SENT Besides_IN the_DT homology_NN with_IN NorM_NP ,_, NorMI_NP also_RB possesses_VBZ 22.2_CD to_TO 28.6_CD %_NN amino_NN acid_JJ identity_NN to_TO the_DT E._NP coli_NNS YdhE_NP protein_NN ,_, the_DT B._NP thetaiotaomicron_NP BexA_NP protein_NN ,_, the_DT V._NP parahaemolyticus_NP VmrA_NP protein_NN ,_, the_DT Arabidopsis_NP Alf5_NP protein_NN ,_, and_CC the_DT yeast_NN Erc1_JJ protein_NN ._SENT No_DT homology_NN was_VBD found_VBN with_IN any_DT other_JJ functionally_RB characterized_VBN bacterial_JJ proteins_NNS ._SENT A_DT prediction_NN of_IN transmembrane_NN helices_NNS by_IN using_VBG the_DT TMHMM_NP server_NN (_( version_NN 2.0_CD )_) from_IN the_DT Center_NP for_IN Biological_NP Sequence_NP Analysis_NP revealed_VBD that_IN NorMI_NP possesses_VBZ 12_CD putative_JJ transmembrane_NN helices_NNS ._SENT These_DT data_NNS strongly_RB suggest_VBP that_IN NorMI_NP represents_VBZ a_DT new_JJ member_NN of_IN the_DT MATE_JJ family_NN ._SENT To_TO study_VB the_DT involvement_NN of_IN NorMI_NP in_IN drug_NN efflux_NN ,_, we_PP overexpressed_VBD this_DT protein_NN in_IN the_DT drug-hypersusceptible_JJ E._NP coli_NNS strain_VBP AG100A_NP ,_, which_WDT was_VBD deleted_VBN of_IN the_DT major_JJ multidrug_NN efflux_NN system_NN AcrAB_NP by_IN Okusu_NP et_FW al._FW ._SENT The_DT norMI_NN gene_NN was_VBD cloned_VBN into_IN the_DT pUC19_JJ vector_NN under_IN the_DT control_NN of_IN its_PP$ natural_JJ promoter_NN ._SENT In_IN brief_NN ,_, norMI_NNS was_VBD first_RB amplified_VBN by_IN PCR_NP from_IN the_DT chromosomal_JJ DNA_NN of_IN B._NP melitensis_NN 16_CD M_NN with_IN primers_NNS P7_JJ (_( 5'-TCGGATCCGGGACGGAAATTTGCGCTTTC-3_JJ '_'' )_) and_CC P4_NP (_( 5'-GGAATTCCCTGAAAGGCTTCGGTGCCGC-3_NP '_POS )_) (_( 1_CD muM_NN final_JJ concentration_NN )_) and_CC Pfu_NP DNA_NP polymerase_NN (_( Promega_NP )_) in_IN an_DT iCycler_NN thermocycler_NN (_( Bio-Rad_NP )_) with_IN the_DT following_VBG cycling_NN conditions_NNS :_: one_CD cycle_NN of_IN 2_CD min_NN at_IN 95C_NN ;_: then_RB 35_CD cycles_NNS of_IN 1_CD min_NN at_IN 95C_NN ,_, 30_CD s_NNS at_IN 55C_NN ,_, and_CC 4_CD min_NN at_IN 72C_NP ;_: and_CC finally_RB one_CD cycle_NN of_IN 5_CD min_NN at_IN 72C_NP ._SENT The_DT amplified_VBN DNA_NN fragment_NN was_VBD restricted_VBN with_IN BamHI_NP and_CC EcoRI_NP and_CC inserted_VBN between_IN the_DT BamHI_NP and_CC EcoRI_NP sites_NNS of_IN pUC19_NN ._SENT The_DT resulting_VBG plasmid_NP (_( pUC19-NorMI_NP )_) and_CC pUC19_NN were_VBD then_RB electroporated_VBN separately_RB in_IN E._NP coli_NNS AG100A_NP ._SENT The_DT capacity_NN of_IN the_DT construct_NN to_TO confer_VB drug_NN resistance_NN to_TO E._NP coli_NNS AG100A_NP was_VBD evaluated_VBN by_IN comparing_VBG the_DT susceptibilities_NNS of_IN the_DT strains_NNS carrying_VBG pUC19_NN and_CC pUC19-NorMI_NN to_TO increasing_VBG concentrations_NNS of_IN many_JJ unrelated_JJ drugs_NNS (_( norfloxacin_NP ,_, ciprofloxacin_NP ,_, gentamicin_NN ,_, tetraphenylphosphonium_NN bromide_NN ,_, erythromycin_NN ,_, nalidixic_JJ acid_NN ,_, chloramphenicol_NN ,_, ofloxacin_NP ,_, quinacrine_NN ,_, tetracycline_NN ,_, ethidium_NN bromide_NN ,_, carbonyl_NN cyanide_NN m-chlorophenylhydrazone_NN [_SYM CCCP_NP ]_SYM ,_, and_CC sulfamethoxazole_NN )_) ._SENT Exponentially_RB growing_VBG bacteria_NNS (_( 105_CD )_) were_VBD inoculated_VBN into_IN 5_CD ml_NN of_IN Mueller-Hinton_NP medium_NN containing_VBG twofold-increasing_NN concentrations_NNS of_IN each_DT drug_NN ._SENT For_IN each_DT drug_NN concentration_NN ,_, growth_NN was_VBD monitored_VBN by_IN measuring_VBG the_DT turbidity_NN of_IN the_DT culture_NN at_IN 600_CD nm_NN after_IN 20_CD h_NN of_IN incubation_NN at_IN 37C_JJ under_IN agitation_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, NorMI_NP confers_VBZ increasing_VBG resistance_NN of_IN strain_NN AG100A_NP towards_IN hydrophilic_JJ fluoroquinolones_NNS such_JJ as_IN norfloxacin_NN and_CC ciprofloxacin_NN ,_, to_TO aminoglycosides_NNS such_JJ as_IN gentamicin_NN ,_, and_CC to_TO the_DT tetraphenylphosphonium_NN cation_NN ._SENT A_DT slight_JJ increase_NN of_IN resistance_NN to_TO acriflavine_NN and_CC berberine_NN was_VBD also_RB observed_VBN ._SENT On_IN the_DT other_JJ hand_NN ,_, AG100A_NP carrying_NN pUC19_NN and_CC pUC19-NorMI_NNS showed_VBD indistinguishable_JJ susceptibilities_NNS to_TO the_DT other_JJ antimicrobial_JJ agents_NNS tested_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT substrate_NN specificity_NN of_IN NorMI_NP is_VBZ highly_RB similar_JJ to_TO that_DT of_IN YdhE_NP of_IN E._NP coli_NNS ._SENT Indeed_RB ,_, like_IN NorMI_NP ,_, YdhE_NP confers_VBZ resistance_NN to_TO norfloxacin_NN ,_, ciprofloxacin_NP ,_, acriflavine_NN ,_, berberine_NN ,_, and_CC tetraphenylphosphonium_NN ion_NN ._SENT Although_IN the_DT specificity_NN of_IN YdhE_NP resistance_NN to_TO gentamicin_NN was_VBD not_RB tested_VBN ,_, this_DT protein_NN confers_VBZ resistance_NN to_TO similar_JJ aminoglycosides_NNS such_JJ as_IN kanamycin_NN and_CC streptomycin_NN ._SENT These_DT results_NNS indicated_VBD that_IN NorMI_NP mediates_VBZ multidrug_NN resistance_NN ._SENT The_DT contribution_NN of_IN NorMI_NP to_TO the_DT drug_NN resistance_NN of_IN B._NP melitensis_NN was_VBD tentatively_RB approached_VBN by_IN disrupting_VBG norMI_NNS in_IN this_DT strain_NN ._SENT Briefly_RB ,_, a_DT kanamycin_NN resistance_NN cassette_NN extracted_VBN from_IN pUC-4K_NN (_( Pharmacia_NP Biotech_NP )_) by_IN EcoRI_NP restriction_NN was_VBD inserted_VBN into_IN the_DT unique_JJ BssHII_NP site_NN of_IN the_DT pUC19-NorMI_NN construct_NN ,_, a_DT suicide_NN vector_NN for_IN Brucella_NP spp._NP After_IN introduction_NN of_IN this_DT construct_NN in_IN B._NP melitensis_NN cells_NNS by_IN electroporation_NN ,_, kanamycin-resistant_NN clones_NNS were_VBD selected_VBN and_CC tested_VBN by_IN PCR_NP to_TO confirm_VB the_DT correct_JJ insertion_NN of_IN the_DT kanamycin_NN cassette_NN and_CC the_DT disruption_NN of_IN norMI_NNS ._SENT A_DT disruption_NN mutant_NN was_VBD selected_VBN ,_, and_CC its_PP$ susceptibility_NN to_TO ciprofloxacin_NN ,_, one_CD of_IN the_DT best_JJS substrates_NNS of_IN NorMI_NP ,_, was_VBD compared_VBN with_IN that_DT of_IN the_DT wild-type_NN strain_NN ._SENT This_DT was_VBD done_VBN as_IN described_VBN above_IN for_IN E._NP coli_NNS ,_, except_IN that_WDT 107_CD cells_NNS inoculated_VBN into_IN 5_CD ml_NN of_IN Trypticase_NP soy_NN broth_NN (_( Difco_NP Laboratories_NP )_) supplemented_VBD with_IN 0.1_CD %_NN yeast_NN extract_NN were_VBD used_VBN ._SENT The_DT mutant_NN and_CC wild-type_NN strains_NNS showed_VBD indistinguishable_JJ susceptibilities_NNS to_TO ciprofloxacin_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT number_NN of_IN other_JJ putative_JJ efflux_NN pumps_NNS (_( including_VBG seven_CD homologs_NNS of_IN the_DT major_JJ E._NP coli_NNS AcrAB_NP pump_NN ,_, at_IN least_JJS three_CD homologs_NNS of_IN the_DT E._NP coli_NNS EmrAB_NP pump_NN ,_, and_CC two_CD ABC_NP transporters_NNS similar_JJ to_TO those_DT involved_VBN in_IN drug_NN efflux_NN )_) are_VBP encoded_VBN by_IN the_DT B._NP melitensis_NN genome_NN ._SENT Those_DT pumps_NNS may_MD well_RB mask_VB the_DT effect_NN of_IN the_DT norMI_NN mutation_NN ,_, and_CC for_IN this_DT reason_NN ,_, we_PP were_VBD obliged_VBN to_TO analyze_VB the_DT function_NN of_IN NorMI_NP in_IN E._NP coli_NNS cells_NNS previously_RB mutated_VBN in_IN their_PP$ major_JJ AcrAB_NP pump_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_NN of_IN drugs_NNS on_IN growth_NN of_IN E._NP coli_NNS Effect_NN of_IN drugs_NNS on_IN growth_NN of_IN E._NP coli_NNS cells_NNS expressing_VBG or_CC not_RB expressing_VBG the_DT NorMI_NP protein_NN of_IN B._NP melitensis_NN ._SENT E._NP coli_NNS AG100A_NP harboring_VBG a_DT vector_NN expressing_VBG NorMI_NP from_IN B._NP melitensis_NP (_( pUC19-NorMI_NP )_) or_CC harboring_VBG the_DT vector_NN alone_RB (_( pUC19_NN )_) was_VBD grown_VBN for_IN 20_CD h_NN at_IN 37C_JJ (_( with_IN agitation_NN )_) in_IN Mueller-Hinton_NP medium_NN containing_VBG twofold-increasing_NN concentrations_NNS of_IN norfloxacin_NN (_( 1.5625_CD to_TO 200_CD ng/ml_NNS )_) ,_, ciprofloxacin_NN (_( 0.3125_CD to_TO 40_CD ng/ml_NNS )_) ,_, gentamicin_NN (_( 31.25_CD to_TO 4,000_CD ng/ml_NNS )_) ,_, tetraphenylphosphonium_NN bromide_NN (_( 1_CD to_TO 128_CD mug/ml_NN )_) ,_, acriflavine_NN (_( 0.25_CD to_TO 32_CD mug/ml_NN )_) ,_, or_CC berberine_NN (_( 3.125_CD to_TO 400_CD mug/ml_NN )_) ._SENT Bacterial_JJ growth_NN was_VBD monitored_VBN by_IN turbidimetry_NN (_( at_IN 600_CD nm_NN )_) ._SENT The_DT growth_NN index_NN ,_, calculated_VBN by_IN dividing_VBG the_DT OD600_NP of_IN the_DT culture_NN in_IN the_DT presence_NN of_IN drug_NN by_IN the_DT OD600_NP of_IN the_DT culture_NN in_IN the_DT absence_NN of_IN drug_NN ,_, is_VBZ shown_VBN ._SENT dependent_JJ efflux_NN ._SENT :_: To_TO investigate_VB the_DT mechanism_NN by_IN which_WDT NorMI_NP confers_VBZ multidrug_NN resistance_NN ,_, we_PP compared_VBD the_DT norfloxacin_NN accumulation_NN in_IN E._NP coli_NNS AG100A_NP cells_NNS harboring_VBG the_DT pUC19-NorMI_NN construct_NN with_IN that_WDT observed_VBD in_IN E._NP coli_NNS AG100A_NP containing_VBG pUC19_NN alone_RB ._SENT We_PP also_RB measured_VBD the_DT effect_NN of_IN CCCP_NP ,_, a_DT proton_NN motive_NN force_NN uncoupler_NN ,_, on_IN the_DT accumulation_NN of_IN norfloxacin_NN inside_IN the_DT cells_NNS ._SENT Norfloxacin_NP accumulation_NN was_VBD assayed_VBN by_IN the_DT method_NN of_IN Mortimer_NP and_CC Piddock_NP with_IN some_DT modifications_NNS ._SENT Briefly_RB ,_, bacteria_NNS were_VBD grown_VBN in_IN Luria-Bertani_NP broth_NN at_IN 37C_JJ to_TO the_DT mid-log_NN phase_NN of_IN growth_NN (_( optical_JJ density_NN at_IN 600_CD nm_NN [_SYM OD600_NP ]_SYM =_SYM 0.6_CD )_) ,_, harvested_VBN by_IN centrifugation_NN ,_, washed_VBN in_IN 50_CD mM_NP sodium_NN phosphate_NN buffer_NN (_( pH_NN 7.0_CD )_) ,_, and_CC resuspended_VBD in_IN the_DT same_JJ buffer_NN to_TO an_DT OD600_NP of_IN 6.0_CD (_( corresponding_VBG to_TO 10_CD mg_NN [_SYM wet_JJ weight_NN ]_SYM per_FW ml_NN )_) ._SENT After_IN incubation_NN for_IN 20_CD min_NN at_IN 37C_JJ ,_, norfloxacin_JJ (_( final_JJ concentration_NN ,_, 100_CD muM_NN )_) was_VBD added_VBN to_TO the_DT bacterial_JJ suspension_NN ._SENT Fifteen_CD minutes_NNS after_IN the_DT addition_NN of_IN norfloxacin_NN ,_, the_DT efflux_NN pump_NN inhibitor_NN CCCP_NP was_VBD added_VBN to_TO the_DT assay_NN mixture_NN at_IN a_DT final_JJ concentration_NN of_IN 100_CD muM_NN ._SENT Samples_NNS (_( 1_CD ml_NN each_DT )_) were_VBD removed_VBN at_IN different_JJ times_NNS after_IN the_DT addition_NN of_IN norfloxacin_NN ,_, centrifuged_VBN at_IN 7,000_CD x_NN g_NN for_IN 30_CD s_NNS at_IN 4C_JJ ,_, washed_VBN once_RB with_IN 1_CD ml_NN of_IN the_DT above-described_JJ ice-cold_JJ phosphate_NN buffer_NN ,_, and_CC resuspended_VBD in_IN 1_CD ml_NN of_IN 100_CD mM_NP glycine-HCl_NN (_( pH_NN 3.0_CD )_) ._SENT The_DT suspension_NN was_VBD shaken_VBN for_IN 20_CD h_NN at_IN room_NN temperature_NN and_CC then_RB centrifuged_VBN at_IN 7,000_CD x_NN g_NN for_IN 5_CD min_NN ._SENT The_DT fluorescence_NN of_IN the_DT supernatant_JJ was_VBD measured_VBN in_IN a_DT Jasco_NP FP-770_NP spectrofluorimeter_NN at_IN excitation_NN and_CC emission_NN wavelengths_NNS of_IN 277_CD and_CC 448_CD nm_NN ,_, respectively_RB ._SENT The_DT concentration_NN of_IN norfloxacin_NN in_IN the_DT supernatant_JJ was_VBD calculated_VBN by_IN comparison_NN with_IN the_DT fluorescence_NN of_IN norfloxacin_NN standards_NNS (_( 0.161_CD to_TO 5_CD nmol/ml_NN )_) in_IN 100_CD mM_NP glycine-HCl_NN (_( pH_NN 3.0_CD )_) ._SENT As_IN shown_VBN in_IN Fig._NN ,_, at_IN 15_CD min_NN after_IN addition_NN of_IN norfloxacin_NN ,_, E._NP coli_NNS AG100A_NP cells_NNS expressing_VBG NorMI_NP accumulated_VBN about_IN fourfold_RB less_JJR norfloxacin_NN than_IN the_DT control_NN cells_NNS ._SENT Addition_NN of_IN the_DT protonophore_NN CCCP_NP induced_VBD an_DT increase_NN of_IN this_DT accumulation_NN ,_, which_WDT reached_VBD rapidly_RB a_DT level_NN similar_JJ to_TO that_WDT observed_VBD in_IN control_NN cells_NNS ._SENT These_DT results_NNS indicated_VBD that_IN NorMI_NP mediates_VBZ an_DT active_JJ efflux_NN process_NN driven_VBN by_IN an_DT electrochemical_JJ potential_NN of_IN H+_NP ._SENT By_IN comparison_NN with_IN most_RBS known_VBN bacterial_JJ multidrug_NN efflux_NN proteins_NNS ,_, it_PP is_VBZ very_RB likely_JJ that_IN NorMI_NP is_VBZ a_DT drug/ion_NN antiporter_NN ._SENT In_IN conclusion_NN ,_, NorMI_NP is_VBZ the_DT first_RB described_VBN protein_NN of_IN B._NP melitensis_NN that_WDT is_VBZ able_JJ to_TO mediate_VB drug_NN resistance_NN by_IN an_DT active_JJ efflux_NN mechanism_NN ._SENT The_DT existence_NN of_IN such_PDT a_DT multidrug_NN transporter_NN indicates_VBZ that_IN ,_, even_RB if_IN drug_NN resistance_NN is_VBZ not_RB considered_VBN a_DT major_JJ problem_NN in_IN treating_VBG brucellosis_NN ,_, it_PP is_VBZ necessary_JJ to_TO control_VB the_DT sensitivity_NN patterns_NNS of_IN Brucella_NP spp._NP to_TO ensure_VB appropriate_JJ treatment_NN and_CC prevent_VB increasing_VBG development_NN of_IN antibiotic_JJ resistance_NN in_IN these_DT bacteria_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Accumulation_NP of_IN norfloxacin_NN in_IN E._NP coli_NNS Accumulation_NP of_IN norfloxacin_NN in_IN E._NP coli_NNS cells_NNS expressing_VBG or_CC not_RB expressing_VBG the_DT NorMI_NP protein_NN of_IN B._NP melitensis_NN ._SENT E._NP coli_NNS AG100A_NP harboring_VBG a_DT vector_NN expressing_VBG NorMI_NP (_( pUC19-NorMI_NP )_) or_CC harboring_VBG pUC19_NN alone_RB was_VBD grown_VBN in_IN Luria-Bertani_NP broth_NN ._SENT Norfloxacin_NP was_VBD added_VBN to_TO the_DT cell_NN suspensions_NNS at_IN a_DT final_JJ concentration_NN of_IN 100_CD muM_NN ._SENT After_IN 15_CD min_NN ,_, CCCP_NP was_VBD added_VBN to_TO the_DT suspensions_NNS at_IN a_DT final_JJ concentration_NN of_IN 100_CD muM_NN ._SENT Samples_NNS were_VBD removed_VBN at_IN the_DT indicated_JJ times_NNS ,_, and_CC the_DT concentration_NN of_IN norfloxacin_NN extracted_VBN from_IN the_DT cells_NNS was_VBD quantified_VBN by_IN spectrofluorimetry_NN ._SENT 